Bob Löwenberg

Q: What Schools Are Affiliated With Bob Löwenberg

Bob Löwenberg is affiliated with the following schools: University of Amsterdam, University of Teramo, Erasmus University Rotterdam, Duke University, University of Münster

Bob Löwenberg's AcademicInfluence.com Rankings

Bob Löwenberg

Computer Science

#3338

World Rank

#3501

Historical Rank

Machine Learning

#373

World Rank

#378

Historical Rank

Artificial Intelligence

#567

World Rank

#578

Historical Rank

Database

#754

World Rank

#791

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Bob Löwenberg Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Bob Löwenberg is a clinical hematologist/investigator. He is Professor of Hematology at Erasmus University Rotterdam. Education He graduated as MD at the University of Groningen , completed a PhD in Experimental Hematology at Erasmus University and Radiobiological Institute TNO, Rijswijk under the supervisorship of Dirk W. van Bekkum and completed his clinical training in Internal Medicine and Hematology, University Hospital Rotterdam, .

(See a Problem?)

Bob Löwenberg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (2017) (3878)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. (2010) (3011)
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. (2003) (2541)
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. (2010) (2405)
Prognostically useful gene-expression profiles in acute myeloid leukemia. (2004) (1390)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. (2006) (1349)
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (2008) (894)
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. (2001) (861)
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. (2010) (807)
High-dose daunorubicin in older patients with acute myeloid leukemia. (2009) (754)
Therapeutic advances in acute myeloid leukemia. (2011) (738)
Report of an international working group to standardize response criteria for myelodysplastic syndromes. (2000) (710)
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. (2005) (637)
Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. (2008) (566)
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. (2009) (565)
A 17-gene stemness score for rapid determination of risk in acute leukaemia (2016) (531)
A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia (2014) (518)
Molecular Minimal Residual Disease in Acute Myeloid Leukemia (2018) (482)
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? (2007) (467)
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. (1997) (463)
Prognostic index for adult patients with acute myeloid leukemia in first relapse. (2005) (461)
Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. (1995) (451)
MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. (2008) (428)
Acute myeloid leukemia. (1999) (425)
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence (2005) (422)
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. (2003) (394)
Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. (2002) (387)
On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. (1989) (383)
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. (2010) (379)
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. (2013) (378)
Clonogenic cells in acute myeloblastic leukemia. (1986) (375)
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach (2012) (363)
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. (2003) (361)
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. (2011) (356)
Minimal Residual Disease in Acute Leukemia (1984) (354)
Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias (2003) (349)
Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. (2000) (339)
Modulation of multidrug-resistant multiple myeloma by cyclosporin (1992) (334)
Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling (2009) (325)
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. (2019) (319)
Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT. (2001) (316)
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. (2008) (309)
Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia‐associated invasive fungal infections (1998) (309)
Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. (2001) (299)
Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene (2000) (299)
Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. (1995) (289)
Base-Pair Resolution DNA Methylation Sequencing Reveals Profoundly Divergent Epigenetic Landscapes in Acute Myeloid Leukemia (2012) (284)
Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. (2004) (280)
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia (2016) (279)
High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. (2008) (276)
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. (2009) (272)
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and (1998) (271)
Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. (2008) (265)
Distinct cytoplasmic regions of the human granulocyte colony-stimulating factor receptor involved in induction of proliferation and maturation (1993) (257)
Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. (2003) (253)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. (2022) (249)
The glucocorticoid receptor cooperates with the erythropoietin receptor and c-Kit to enhance and sustain proliferation of erythroid progenitors in vitro. (1999) (249)
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. (2018) (245)
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. (2010) (243)
Mutations in N-ras predominate in acute myeloid leukemia. (1987) (238)
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. (2012) (237)
Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. (2001) (235)
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. (2010) (234)
Hematopoietic growth factors and their receptors in acute leukemia. (1993) (225)
Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. (2022) (218)
Cytarabine dose for acute myeloid leukemia. (2011) (215)
Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. (2007) (215)
Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database (2006) (215)
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. (2010) (210)
Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. (1991) (199)
Identification of a nonsense mutation in the granulocyte-colony-stimulating factor receptor in severe congenital neutropenia. (1994) (198)
FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1 (2004) (192)
How I treat the older patient with acute myeloid leukemia. (2015) (187)
Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. (1993) (184)
Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. (2002) (175)
Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. (2012) (168)
Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia (1997) (167)
Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. (1993) (166)
Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). (1997) (165)
Somatostatin and the immune and haematopoetic system; a review (1994) (164)
Growth regulation of human acute myeloid leukemia: effects of five recombinant hematopoietic factors in a serum-free culture system (1988) (161)
Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. (2009) (161)
Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. (1990) (160)
Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. (2012) (156)
Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia (2014) (155)
Autologous hematopoietic stem cell transplantation for autoimmune diseases (2005) (155)
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. (2005) (151)
miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia (2012) (148)
Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value (2012) (146)
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. (2008) (144)
Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe : further evidence of the role of marrow purging by mafosfamide (1991) (144)
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. (2013) (142)
Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. (2013) (141)
Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. (2003) (141)
Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. (1990) (140)
Interleukin-3 and granulocyte-monocyte colony-stimulating factor receptors on human acute myelocytic leukemia cells and relationship to the proliferative response. (1989) (139)
MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1-regulated pathways in mice. (2011) (139)
Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. (2013) (138)
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. (1997) (137)
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. (2013) (137)
STAT3-mediated differentiation and survival of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27Kip1 (2000) (136)
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. (2007) (135)
Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia. (2020) (134)
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. (2010) (133)
Human recombinant multilineage colony stimulating factor (interleukin-3): stimulator of acute myelocytic leukemia progenitor cells in vitro. (1987) (133)
Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center (2014) (132)
Acute myeloid leukemia and acute promyelocytic leukemia. (2003) (131)
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. (2011) (130)
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. (2012) (129)
Acute myeloid leukemia: the challenge of capturing disease variety. (2008) (126)
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years (2014) (126)
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. (2004) (122)
Perturbed granulopoiesis in mice with a targeted mutation in the granulocyte colony-stimulating factor receptor gene associated with severe chronic neutropenia. (1998) (120)
PBX3 is an important cofactor of HOXA9 in leukemogenesis. (2013) (119)
Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells. (1997) (117)
Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture. (1996) (116)
Granulocyte colony-stimulating factor receptors in human acute myelocytic leukemia. (1989) (114)
Molecular epidemiology of apparent outbreak of invasive aspergillosis in a hematology ward (1996) (114)
Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis (2005) (113)
Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. (2011) (111)
Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. (2011) (110)
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. (2011) (109)
MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia (1997) (108)
Dynamics of Protein Binding to Telomeres in Living Cells: Implications for Telomere Structure and Function (2004) (108)
Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. (1995) (107)
A point mutation in the granulocyte colony-stimulating factor receptor (G-CSF-R) gene in a case of acute myeloid leukemia results in the overexpression of a novel G-CSF-R isoform. (1995) (107)
Splenectomy for the treatment of thrombotic thrombocytopenic purpura (2005) (107)
Stem cell factor induces phosphatidylinositol 3'-kinase-dependent Lyn/Tec/Dok-1 complex formation in hematopoietic cells. (2000) (106)
Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. (2011) (105)
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age (2007) (104)
Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first‐line treatment in untreated multiple myeloma (1999) (104)
Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. (2019) (103)
Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. (2013) (103)
Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein–Barr virus‐associated lymphoproliferative disease after allogeneic stem cell transplantation (2001) (102)
Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. (1996) (102)
Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. (2009) (101)
A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. (2009) (100)
The membrane-distal cytoplasmic region of human granulocyte colony-stimulating factor receptor is required for STAT3 but not STAT1 homodimer formation. (1996) (100)
Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. (2013) (100)
On the road to new drugs in acute myeloid leukemia. (2006) (99)
Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. (1997) (99)
CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia (2018) (98)
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. (2020) (98)
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. (2011) (97)
Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis (2009) (95)
Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. (1996) (95)
Interleukin-6 synergizes with M-CSF in the formation of macrophage colonies from purified human marrow progenitor cells. (1989) (95)
Interleukin-1 stimulates proliferation of acute myeloblastic leukemia cells by induction of granulocyte-macrophage colony-stimulating factor release. (1989) (93)
Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. (1996) (92)
Stimulating spectrum of human recombinant multi-CSF (IL-3) on human marrow precursors: importance of accessory cells. (1988) (92)
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC–HOVON randomized phase III study (06914) (2001) (92)
Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. (1999) (90)
Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. (2009) (90)
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. (2008) (90)
Characterization of a human multilineage-colony-stimulating factor cDNA clone identified by a conserved noncoding sequence in mouse interleukin-3. (1987) (88)
High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. (2010) (88)
Specific involvement of tyrosine 764 of human granulocyte colony-stimulating factor receptor in signal transduction mediated by p145/Shc/GRB2 or p90/GRB2 complexes. (1996) (88)
Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis (1992) (87)
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. (2013) (85)
Somatostatin analogue scintigraphy of malignant lymphomas (1993) (85)
Differential Regulation of Foxo3a Target Genes in Erythropoiesis (2007) (85)
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. (2007) (84)
Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. (2009) (84)
Long-term leukemia-initiating capacity of a CD34-subpopulation of acute myeloid leukemia. (1996) (84)
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. (2012) (83)
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia (2019) (80)
The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. (2004) (80)
Common binding structure for granulocyte macrophage colony-stimulating factor and interleukin-3 on human acute myeloid leukemia cells and monocytes. (1990) (80)
MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML. (2018) (80)
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. (2015) (80)
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy (2010) (79)
Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain. (1996) (78)
Including historical data in the analysis of clinical trials: Is it worth the effort? (2017) (78)
AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion. (2005) (78)
Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. (2019) (77)
Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia (2005) (77)
Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias (2008) (76)
Monitoring cytomegalovirus IE‐1 and pp65‐specific CD4+ and CD8+ T‐cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations (2008) (76)
Interleukin-7 improves T-cell recovery after experimental T-cell-depleted bone marrow transplantation in T-cell-deficient mice by strong expansion of recent thymic emigrants. (2003) (75)
Towards precision medicine for AML (2021) (75)
Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia. (2015) (75)
Influence of interferon preparations on the proliferative capacity of human and mouse bone marrow cells in vitro. (1978) (75)
Tryptophan 650 of human granulocyte colony-stimulating factor (G-CSF) receptor, implicated in the activation of JAK2, is also required for G-CSF-mediated activation of signaling complexes of the p21ras route. (1996) (74)
Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. (2015) (74)
Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. (1989) (74)
Karyotypically distinct subpopulations in acute leukemia with specific growth requirements. (1982) (74)
Common and pre-B acute lymphoblastic leukemia cells express interleukin 2 receptors, and interleukin 2 stimulates in vitro colony formation. (1985) (73)
Proliferation signaling and activation of Shc, p21Ras, and Myc via tyrosine 764 of human granulocyte colony-stimulating factor receptor. (1998) (73)
Minimal residual disease in chronic myeloid leukemia. (2003) (72)
Tumor necrosis factor regulates the expression of granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors on human acute myeloid leukemia cells. (1991) (72)
Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch–Belgian Haemato‐Oncology Co‐operative Group (HOVON) and Swiss Group for Clinical Cancer Research (2005) (72)
Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group. (1997) (72)
Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy. (2010) (71)
PHA-induced colony formation in acute non-lymphocytic and chronic myeloid leukemia. (1980) (71)
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. (2017) (71)
Positive and negative effects of tumor necrosis factor on colony growth from highly purified normal marrow progenitors. (1991) (71)
Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989–2012 (2016) (70)
Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16). (2004) (70)
Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia? (1999) (69)
MOLECULAR CHARACTERIZATION OF MUTANT TP53 ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME. (2022) (68)
Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. (2010) (68)
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). (2012) (68)
Prognostic factors in acute myeloid leukaemia. (2001) (67)
Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia. (2016) (67)
Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia (2007) (65)
Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. (1995) (65)
Protein Kinase C α Controls Erythropoietin Receptor Signaling* (2000) (64)
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. (2020) (64)
Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). (1995) (64)
The incidence of herpes zoster in patients with Hodgkin's disease an analysis of prognostic factors (1985) (63)
DELAYED ALLOIMMUNISATION BY RANDOM SINGLE DONOR PLATELET TRANSFUSIONS A Randomised Study to Compare Single Donor and Multiple Donor Platelet Transfusions in Cancer Patients with Severe Thrombocytopenia (1981) (63)
Btk Is Required for an Efficient Response to Erythropoietin and for SCF-controlled Protection against TRAIL in Erythroid Progenitors (2004) (62)
Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial (2007) (62)
In situ hybridization on May-Grünwald Giemsa-stained bone marrow and blood smears of patients with hematologic disorders allows detection of cell-lineage-specific cytogenetic abnormalities. (1993) (62)
Tumor necrosis factor downregulates granulocyte-colony-stimulating factor receptor expression on human acute myeloid leukemia cells and granulocytes. (1991) (62)
The genes encoding the peripheral cannabinoid receptor and alpha-L-fucosidase are located near a newly identified common virus integration site, Evi11 (1997) (62)
Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON‐SAKK co‐operative group studies (2005) (61)
The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML (2013) (61)
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio (2016) (61)
Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients. (2012) (61)
AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance. (2009) (60)
Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions (2018) (59)
The E3 ubiquitin-protein ligase Triad1 inhibits clonogenic growth of primary myeloid progenitor cells. (2005) (59)
Further results in understanding the subpopulation structure of AML: clonogenic cells and their progeny identified by differentiation markers. (1985) (59)
Graft-versus-host disease following transplantation of 'one log' versus 'two log' T-lymphocyte-depleted bone marrow from HLA-identical donors. (1986) (59)
Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. (1993) (58)
Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia (2002) (58)
Acute myeloid leukemia and the position of autologous stem cell transplantation. (2007) (57)
Flow cytometric differential of leukocyte populations in normal bone marrow: Influence of peripheral blood contamination1 (2009) (56)
Transplantation of non‐purified autologous bone marrow in patients with AML in first remission (1984) (56)
Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study (2014) (56)
FLT3 inhibition as a targeted therapy for acute myeloid leukemia (2009) (56)
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. (2013) (55)
A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies. (2003) (55)
Human AML colony growth in serum-free culture. (1988) (55)
Chronic myeloid leukemia with permanent disappearance of the Ph1 chromosome and development of new clonal subpopulations. (1979) (54)
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy (2011) (54)
Cytogenetic clonality analysis in myelodysplastic syndrome: monosomy 7 can be demonstrated in the myeloid and in the lymphoid lineage. (1995) (53)
Rapid emergence of ciprofloxacin-resistant enterobacteriaceae containing multiple gentamicin resistance-associated integrons in a Dutch hospital. (2001) (53)
The proliferative response of B cell chronic lymphocytic leukemia to interleukin 2: functional characterization of the interleukin 2 membrane receptors. (1987) (53)
INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia (2015) (52)
Evidence for acute neurotoxicity after chemotherapy (2010) (52)
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. (2015) (51)
A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition (2015) (51)
Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. (2014) (51)
Flt3 Ligand Expands Lymphoid Progenitors Prior to Recovery of Thymopoiesis and Accelerates T Cell Reconstitution after Bone Marrow Transplantation1 (2007) (50)
Sustainability and affordability of cancer drugs: a novel pricing model (2018) (50)
On the maturation order of AML cells: a distinction on the basis of self-renewal properties and immunologic phenotypes (1984) (50)
Effects of recombinant multi-CSF, GM-CSF, G-CSF and M-CSF on the proliferation and maturation of human AML in vitro. (1988) (49)
Large-scale identification of novel potential disease loci in mouse leukemia applying an improved strategy for cloning common virus integration sites (2002) (49)
Erythroid defects and increased retrovirally-induced tumor formation in Evi1 transgenic mice (2000) (49)
A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia. (2007) (48)
The value of the MDR 1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia ( AML ) , in relation to MDR 1 status at diagnosis (48)
Kit ligand improves in vitro erythropoiesis in myelodysplastic syndrome. (1992) (48)
Frequency analysis of multidrug resistance-1 gene transfer into human primitive hematopoietic progenitor cells using the cobblestone area-forming cell assay and detection of vector-mediated P-glycoprotein expression by rhodamine-123. (1996) (48)
Quantification of newly developed T cells in mice by real-time quantitative PCR of T-cell receptor rearrangement excision circles. (2002) (48)
ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients (2006) (47)
Acute myeloid leukemia [4] (multiple letters) (2000) (47)
Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas. (2001) (46)
Distinct Expression Profiles of the Peripheral Cannabinoid Receptor in Lymphoid Tissues Depending on Receptor Activation Status 1 (2004) (45)
Acute myeloid leukemia colony growth in vitro: differences of colony-forming cells in PHA-supplemented and standard leukocyte feeder cultures. (1982) (45)
Impaired health‐related quality of life in acute myeloid leukemia survivors: a single‐center study (2014) (45)
PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells. (2012) (45)
PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway (2014) (45)
Modulation of colony stimulating factor-(CSF) dependent growth of acute myeloid leukemia by tumor necrosis factor. (1990) (45)
[Treatment of elderly patients with acute myeloid leukemia]. (1997) (44)
Autologous bone marrow transplantation in patients with cancer. (1980) (44)
Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia. (1988) (44)
Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome (2017) (44)
A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia: A leukemia‐lymphoma group trial of the EORTC (1986) (44)
The European Cancer Patient’s Bill of Rights, update and implementation 2016 (2016) (44)
ID1 and ID2 are retinoic acid responsive genes and induce a G0/G1 accumulation in acute promyelocytic leukemia cells (2005) (43)
The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia (2014) (43)
Recombinant hematopoietic growth factors fail to induce a proliferative response in precursor B acute lymphoblastic leukemia. (1989) (43)
Acute lymphoblastic leukemia and non-Hodgkin's lymphoma of T lineage: colony-forming cells retain growth factor (interleukin 2) dependence. (1986) (43)
Treatment of the elderly patient with acute myeloid leukaemia. (1996) (43)
Tyrosine kinase receptor RON functions downstream of the erythropoietin receptor to induce expansion of erythroid progenitors. (2004) (43)
Epstein-Barr virus ( EBV ) reactivation is a frequent event after allogeneic hematopoietic stem cell transplantation and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted stem cell transplantation (2002) (42)
Synergistic effects between GM-CSF and G-CSF or M-CSF on highly enriched human marrow progenitor cells. (1990) (42)
Textbook of Malignant Haematology (1999) (42)
The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity (2004) (42)
A catalyst for change: the European cancer Patient's Bill of Rights. (2014) (41)
Pharmacokinetics of Mycophenolate Mofetil in Hematopoietic Stem Cell Transplant Recipients (2007) (41)
Application of myeloid growth factors in the treatment of acute myeloid leukemia (1997) (41)
Patterns of acute myeloid leukemia colony growth in response to recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). (1987) (41)
Interleukin 2 stimulates chronic lymphocytic leukemia colony formation in vitro. (1985) (41)
Segmental uniparental disomy as a recurrent mechanism for homozygous CEBPA mutations in acute myeloid leukemia (2007) (40)
Rapid clearance of cytomegalovirus-specific IgG after repeated intravenous infusions of human immunoglobulin into allogeneic bone marrow transplant recipients. (1987) (40)
The human GFI136N variant induces epigenetic changes at the Hoxa9 locus and accelerates K-RAS driven myeloproliferative disorder in mice. (2012) (40)
A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML. (2007) (40)
P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy (2000) (40)
Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults. (2004) (40)
Rapid simultaneous screening of factor V Leiden and G20210A prothrombin variant by multiplex polymerase chain reaction on whole blood. (1998) (40)
Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? (1999) (39)
Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia. (2005) (39)
Conditions for engraftment of human acute myeloid leukemia (AML) in SCID mice. (1995) (39)
Introduction to the review series on advances in acute myeloid leukemia (AML). (2016) (39)
Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand. (1996) (39)
Somatostatin is a selective chemoattractant for primitive (CD34(+)) hematopoietic progenitor cells. (2002) (39)
Post-remission treatment of acute myelogenous leukemia. (1995) (39)
Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell-depleted grafts from matched unrelated donors: a dose-finding study. (2003) (38)
Somatostatin receptor scintigraphy useful in stage I–II Hodgkin's disease: more extended disease identified (2001) (38)
The peripheral cannabinoid receptor Cb2, a novel oncoprotein, induces a reversible block in neutrophilic differentiation. (2003) (37)
Proliferative response of highly purified B chronic lymphocytic leukemia cells in serum free culture to interleukin-2 and tumor necrosis factors alpha and beta. (1989) (37)
Interleukin-6 (IL-6) is an intermediate in IL-1-induced proliferation of leukemic human megakaryoblasts. (1990) (37)
The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib. (2007) (36)
Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB‐MYH11 gene fusion (2002) (36)
Amsacrine with high-dose cytarabine in acute leukemia. (1985) (36)
Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) (2018) (36)
Blast colony-forming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors. (1993) (36)
Relation between CXCR4 expression , Flt 3 mutations , and unfavorable prognosis of adult acute myeloid leukemia (2004) (35)
A method for cloning T‐lymphocytic precursors in agar (1979) (35)
Stimulation of proliferation and differentiation of acute myeloid leukemia cells on a bone marrow stroma in culture. (1985) (35)
Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group. (1995) (35)
Induction of granulocytic maturation in acute myeloid leukemia by G-CSF and retinoic acid. (1991) (34)
Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia (2005) (34)
Retroviral Insertions in Evi12, a Novel Common Virus Integration Site Upstream of Tra1/Grp94, Frequently Coincide with Insertions in the Gene Encoding the Peripheral Cannabinoid Receptor Cnr2 (1999) (34)
Paradoxical effects of interleukin‐10 on the maturation of murine myeloid dendritic cells (2003) (34)
Different stimulative effects of human bone marrow and fetal liver stromal cells on erythropoiesis in long-term culture. (1987) (33)
HeatMapper: powerful combined visualization of gene expression profile correlations, genotypes, phenotypes and sample characteristics (2006) (33)
Myelodysplastic syndromes standardized response criteria: further definition. (2001) (33)
Significance of murine retroviral mutagenesis for identification of disease genes in human acute myeloid leukemia. (2006) (33)
A phase I first‐in‐human study with tefinostat – a monocyte/macrophage targeted histone deacetylase inhibitor – in patients with advanced haematological malignancies (2013) (33)
Leukemic predisposition of pSca-1/Cb2 transgenic mice. (2002) (33)
Different repopulation kinetics of erythroid (BFU‐E), myeloid (CFU‐GM) and T lymphocyte (TL‐CFU) progenitor cells after autologous and allogeneic bone marrow transplantation (1987) (33)
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies (2015) (32)
Facilitated engraftment of human hematopoietic cells in severe combined immunodeficient mice following a single injection of Cl2MDP liposomes (1997) (32)
Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands. (1995) (32)
Acute myeloid leukemias with chromosomal abnormalities involving the 21q22 region identified by their in vitro responsiveness to interleukin-5. (1991) (32)
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia (2010) (32)
MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia. (2016) (31)
Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RARalpha. (2008) (31)
Anaemia of chronic disease in rheumatoid arthritis (1990) (31)
Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). (1994) (31)
Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum (2011) (31)
Cytogenetic clonality analysis: typical patterns in myelodysplastic syndrome and acute myeloid leukaemia (1996) (31)
Membrane receptors for interleukin 2 on hematopoietic precursors in chronic myeloid leukemia. (1987) (30)
Growth regulation of human acute myeloid leukemia: effects of five recombinant hematopoietic factors in a serum-free culture system. (1988) (30)
Translational Control of Putative Protooncogene Nm23-M2 by Cytokines via Phosphoinositide 3-Kinase Signaling* (2004) (30)
Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. (1994) (30)
Diagnosis and prognosis in acute myeloid leukemia--the art of distinction. (2008) (30)
No stimulative effect of adipocytes on hematopoiesis in long-term human bone marrow cultures. (1983) (30)
Bone Marrow Transplan- tation: Biological Mechanisms and Clinical Practice (1985) (30)
FATAL CEREBRAL TOXOPLASMOSIS IN A BONE MARROW TRANSPLANT RECIPIENT WITH LEUKEMIA (1983) (30)
Translocation (6;9) may be associated with a specific TdT-positive immunological phenotype in ANLL. (1988) (30)
A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group (1998) (30)
Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor eliminates acute myeloid leukemia cells with the potential to initiate leukemia in immunodeficient mice, but spares normal hemopoietic stem cells. (1997) (29)
Primary human acute myeloblastic leukaemia: an analysis of in vitro granulocytic maturation following stimulation with retinoic acid and G‐CSF (1991) (29)
Variable differentiation of human acute myeloid leukaemia during colony formation in vitro: a membrane marker analysis with monoclonal antibodies (1985) (29)
No preferential sensitivity of clonogenic AML cells to ASTA-Z-7557. (1984) (29)
Candida krusei Transmission among Hematology Patients Resolved by Adapted Antifungal Prophylaxis and Infection Control Measures (2006) (28)
The effect of oligonucleotide microarray data pre-processing on the analysis of patient-cohort studies (2006) (28)
Anaemia of chronic disease in rheumatoid arthritis. Raised serum interleukin-6 (IL-6) levels and effects of IL-6 and anti-IL-6 on in vitro erythropoiesis. (1990) (28)
Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial (2017) (28)
Resistance to chemotherapy in acute leukemia (1998) (28)
Identification of a novel CBFB-MYH11 transcript: implications for RT-PCR diagnosis. (2001) (27)
Retroviral Integration Mutagenesis in Mice and Comparative Analysis in Human AML Identify Reduced PTP4A3 Expression as a Prognostic Indicator (2011) (27)
Mutant Wilms’ tumor 1 (WT1) mRNA with premature termination codons in acute myeloid leukemia (AML) is sensitive to nonsense-mediated RNA decay (NMD) (2010) (27)
Treatment of acute myelocytic leukemia with low-dose cytosine arabinoside: results of a pilot study in four patients. (1983) (27)
Impaired iron uptake and transferrin binding by erythroblasts in the anaemia of rheumatoid arthritis. (1990) (27)
Fucose binding lectin for characterizing acute myeloid leukemia progenitor cells. (1986) (27)
Clonality analysis of hematopoietic cell lineages in acute myeloid leukemia and translocation (8;21): only myeloid cells are part of the malignant clone (1997) (26)
Rapid Simultaneous Screening of Factor V Leiden and G20210A Prothrombin Variant by Multiplex Polymerase Chain Reaction on Whole Blood (1998) (26)
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. (2000) (26)
Human granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates immature marrow precursors but no CFU-GM, CFU-G, or CFU-M. (1989) (26)
Acute promyelocytic leukemia with a PLZF-RARα fusion protein (2001) (25)
Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study. (1988) (25)
High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia. (2015) (25)
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. (2008) (25)
Acute myeloid leukaemia with +i(12p) shortly after treatment of mediastinal germ cell tumour (1994) (24)
Interleukin-1 alpha also induces granulocyte-macrophage colony-stimulating factor in immature normal bone marrow cells. (1990) (24)
Effects of human interleukin-3 on granulocytic colony-forming cells in human bone marrow. (1989) (24)
Gene expression profiling in acute myeloid leukemia (2005) (24)
Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age (2016) (24)
The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia (2019) (24)
Transition of highly specific microRNA expression patterns in association with discrete maturation stages of human granulopoiesis (2011) (23)
Hierarchical Bayesian formulations for selecting variables in regression models (2012) (23)
In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry. (1988) (23)
Somatostatin receptor scintigraphy in the initial staging of Hodgkin's disease (1996) (23)
An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture. (1998) (23)
Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations (2014) (23)
Susceptibility of acute myeloid leukemia (AML) cells from clinically resistant and sensitive patients to daunomycin (DNR): assessment in vitro after stimulation with colony stimulating factors (CSFs). (1990) (22)
Ultrasound examination of pathological cervical lymph nodes in patients with non‐Hodgkin's lymphoma and Hodgkin's disease (1994) (22)
The relevance of somatostatin receptor expression in malignant lymphomas. (1996) (22)
Interleukin-3 (IL-3) receptors on rhesus monkey bone marrow cells: species specificity of human IL-3, binding characteristics, and lack of competition with GM-CSF. (1994) (22)
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome (2008) (22)
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1) (2008) (22)
Predictive impact of allele-matching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia (2011) (21)
profile that is uniquely associated with a favorable outcome subgroup of acute myeloid leukemia with a distinctive gene expression mutations, define a CEBPA mutations, but not single CEBPA Double (2009) (21)
A rapid RT-PCR based method to isolate complementary DNA fragments flanking retrovirus integration sites. (1997) (21)
Cytogenetic clonality analysis of megakaryocytes in myelodysplastic syndrome by dual‐color fluorescence in situ hybridization and confocal laser scanning microscopy (1999) (21)
Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission. (2017) (21)
Incomplete chimerism in erythroid, myeloid and B lymphocyte lineage after T cell-depleted allogeneic bone marrow transplantation. (1988) (21)
Phenotyping of acute myelocytic leukemia (AML) progenitors: an approach for tracing minimal numbers of AML cells among normal bone marrow. (1988) (21)
Managing therapy in older adult patients with acute myeloid leukemia. (2001) (21)
Granulocyte-macrophage colony-stimulating factor receptors alter their binding characteristics during myeloid maturation through up-regulation of the affinity converting beta subunit (KH97). (1993) (21)
Low expression of MDS1-EVI1-like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia. (2003) (20)
High dose therapy for acute myelocytic leukemia treatment strategy: what is the choice? (1993) (20)
Effects of mast cell growth factor on acute myeloid leukemia cells in vitro: effects of combinations with other cytokines. (1993) (20)
Eosinophilia and granulocytic dysplasia terminating in acute myeloid leukaemia after 24 years (1996) (20)
Allogeneic bone marrow transplantation for chronic myelogenous leukemia (1993) (19)
Somatostatin and its cyclic octapeptide analog SMS 201-995 as inhibitors of proliferation of human acute lymphoblastic and acute myeloid leukemia. (1995) (19)
Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG (2016) (19)
Improved prognostic significance of cytokine-induced proliferation in vitro in patients with de novo acute myeloid leukemia of intermediate risk: impact of internal tandem duplications in the Flt3 gene (2001) (19)
Haploidentical ‘megadose’ stem cell transplantation in acute leukemia: recommendations for a protocol agreed upon at the Perugia and Chicago meetings (2002) (19)
A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions (1996) (19)
Azathioprine‐associated pure red cell aplasia (1993) (18)
Combining gene mutation with gene expression analysis improves outcomes prediction in acute promyelocytic leukemia. (2019) (18)
Influence of genetic resistance and silica particles on survival after bone marrow transplantation. (1976) (18)
Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. (1998) (18)
Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia (2018) (17)
Effects of fibroblasts on the growth of erythroid progenitor cells in vitro. (1977) (17)
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. (2021) (17)
Strategies in the treatment of acute myeloid leukemia. (2004) (17)
On the maturation order of AML cells: a distinction on the basis of self-renewal properties and immunologic phenotypes. (1984) (17)
Preliminary report of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg (R)) given in combination with cytarabine and daunorubicin in patients with acute myeloid leukemia (2001) (17)
Strict infection control measures do not prevent clonal spread of coagulase negative staphylococci colonizing central venous catheters in neutropenic hemato-oncologic patients. (2003) (17)
Nature of the delayed graft-versus-host reactivity of fetal liver cell transplants in mice. (1977) (17)
Enhanced chemosensitivity in acute myeloid leukemia by hematopoietic growth factors: a comparison of the MTT assay with a clonogenic assay. (1993) (17)
SNPExpress: integrated visualization of genome-wide genotypes, copy numbers and gene expression levels (2008) (17)
Developments in T-cell depletion of allogeneic stem cell grafts. (2000) (17)
Hematopoietic growth factor receptors: structure variations and alternatives of receptor complex formation in normal hematopoiesis and in hematopoietic disorders. (1995) (17)
T-lymphocyte reconstitution following rigorously T-cell-depleted versus unmodified autologous stem cell transplants (2006) (17)
Keratinocyte Growth Factor Induces Expansion of Murine Peripheral CD4+Foxp3+ Regulatory T Cells and Increases Their Thymic Output1 (2007) (16)
Hemopoietin-1 activity of interleukin-1 (IL-1) on acute myeloid leukemia colony-forming cells (AML-CFU) in vitro: IL-1 induces production of tumor necrosis factor-alpha which synergizes with IL-3 or granulocyte-macrophage colony-stimulating factor. (1990) (16)
Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI (2016) (16)
A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation. (2005) (16)
A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies. (2004) (16)
Internalization‐defective mutants of somatostatin receptor subtype 2 exert normal signaling functions in hematopoietic cells (2001) (16)
Involvement of tumor necrosis factor (TNF) receptors p55 and p75 in TNF responses of acute myeloid leukemia blasts in vitro. (1992) (15)
NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia (2020) (15)
The value of a 51Cr platelet lysis assay as crossmatch test in patients with leukaemia on platelet transfusion therapy (1986) (15)
Strategies in the treatment of acute myeloid leukemia. (2004) (15)
Homogeneous antibodies in lethally irradiated and autologous bone marrow reconstituted Rhesus monkeys (1976) (15)
Improving the Treatment Outcome of Acute Promyelocytic Leukemia in Developing Countries through International Cooperative Network. Report On the International Consortium On Acute Promyelocytic Leukemia Study Group. (2009) (15)
The expression of the Peripheral Cannabinoid receptor on cells of the immune system and Non-Hodgkin's lymphomas (2007) (14)
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (2020) (14)
Characterization of clonogenic cells in refractory anemia with excess of blasts (RAEB-CFU): response to recombinant hematopoietic growth factors and maturation phenotypes. (1989) (14)
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (2020) (14)
Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study. (1996) (14)
Phenotyping of Evi1, Evi11/Cb2, and Evi12 transformed leukemias isolated from a novel panel of cas-Br-M murine leukemia virus-infected mice. (2000) (14)
Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment (1998) (14)
The C-terminal cytoplasmic region of the granulocyte colony-stimulating factor receptor mediates apoptosis in maturation-incompetent murine myeloid cells. (1996) (14)
Dexamethasone does not counteract the response of acute promyelocytic leukaemia cells to all‐trans retinoic acid (1999) (14)
Efficient long-term maintenance of chronic myeloid leukemic cobblestone area forming cells on a murine stromal cell line (1997) (13)
Keratinocyte Growth Factor Induces Expansion of Murine Peripheral CD4 Foxp3 Regulatory T Cells and Increases Their Thymic Output (2007) (13)
Minimal Residual Disease in Acute Leukemia 1986 (1986) (13)
A retrospective Dutch study comparing T cell-depleted allogeneic blood stem cell transplantation vs T cell-depleted allogeneic bone marrow transplantation. (1998) (13)
Autologous stem-cell transplantation and purging. (1996) (13)
Induction of proliferation of haemopoietic stem cells in culture. (1977) (13)
Production of T lymphocyte colony-forming units from precursors in human long-term bone marrow cultures. (1984) (13)
Density profiles and purification of chronic myeloid leukemia cells forming colonies in the PHA-leukocyte feeder assay. (1981) (13)
Towards Detection of Minimal Disease: Discrimination of AML Precursors from Normal Myeloid Precursors using a Combination of Surface Markers (1986) (13)
Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients (2019) (12)
Quantitative aspects of fetal liver cell transplantation in animals and man. (1976) (12)
Disappearance of trisomy 8 after alpha-2 interferon in a patient with myelodysplastic syndrome. (1988) (12)
Studies on chronic myeloid leukemia cell populations with colony-forming abilities in PHA-leukocyte feeder and Robinson assays. (1982) (12)
Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all‐trans retinoic acid and anthracycline‐based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study (2014) (12)
Cost analysis of CHOP (‐like) chemotherapy regimens for patients with newly diagnosed aggressive non‐Hodgkin's lymphoma (2002) (12)
The impact of abn(17p) and monosomy -5/del(5q) on the prognostic value of the monosomal karyotype in acute myeloid leukemia. (2013) (12)
Molecular Minimal Residual Disease in Acute Myeloid Leukemia. (2018) (12)
RUNX1 GERMLINE VARIANTS IN RUNX1-MUTANT AML: HOW FREQUENT? (2020) (12)
Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676). (2000) (12)
Vim-2, candidate monoclonal antibody for purging autologous marrow grafts in acute myeloblastic leukaemia. (1987) (11)
Characterization of normal and regenerating bone marrow cells with a panel of monoclonal antibodies. (2009) (11)
The Development and Validation of a Decision-Analytic Model Representing the Full Disease Course of Acute Myeloid Leukemia (2013) (11)
Detection of the blastic crisis cell clone in chronic myeloid leukaemia (1985) (11)
Somatostatin modulates G-CSF-induced but not interleukin-3-induced proliferative responses in myeloid 32D cells via activation of somatostatin receptor subtype 2. (2001) (11)
A comparison of in vitro sensitivity of acute myeloid leukemia precursors to mitoxantrone, 4'deoxydoxorubicin, 4-demethoxydaunorubicin and daunorubicin. (1986) (11)
Retinoic acid receptor fusion proteins: friend or foe (2000) (11)
Allogeneic bone marrow transplantation in patients with multiple myeloma (1989) (11)
Feeder cell requirements for leukemia cell colony formation in cultures supplemented with phytohemagglutinin. (1984) (11)
Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (2018) (11)
Detection of CEBPA double mutants in acute myeloid leukemia using a custom gene expression array. (2013) (11)
The value of alloantibody detection in predicting response to HLA‐matched platelet transfusions (2004) (11)
An assay for serum cytotoxicity against erythroid precursor cells in pure red cell aplasia. (1977) (11)
Identification of Molecular Predictors of Response to ZARNESTRA™ (Tipifarnib, R115777) in Relapsed and Refractory Acute Myeloid Leukemia. (2004) (10)
PBX 3 is an important cofactor of HOXA 9 in leukemogenesis * (2013) (10)
Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD1152, in Patients with Advanced Acute Myeloid Leukemia. (2009) (10)
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy (2018) (10)
Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia. (2017) (10)
Interleukin 2: Its role in the proliferation of neoplastic T and B cells (1986) (10)
Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy (2018) (10)
Pap tests may detect other cancers (2013) (10)
Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG (2015) (10)
STAT3beta does not interfere with granulocyte colony-stimulating factor-induced neutrophilic differentiation. (2000) (10)
Somatostatin induces migration of acute myeloid leukemia cells via activation of somatostatin receptor subtype 2 (2001) (10)
Phagocytic plasma cells in a patient with multiple myeloma. (1995) (10)
A characterization of T lymphocyte colony-forming cells (TL-CFC) in human bone marrow. (1980) (10)
In Vitro Colony Forming Cells of Acute Lymphoblastic Leukemia: Analysis of 24 Cases with Recombinant Interleukin 2 as Growth Stimulus (1986) (10)
Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma. (2000) (9)
The hematologic mission and scope of the Journal in 2013: Blood, a podium for clinical studies and a podium for experimental research in hematology. (2013) (9)
Rapid Emergence of Ciprofloxacin-Resistant Enterobacteriaceae Containing Multiple Gentamicin Resistance-Associated Integrons, the Netherlands (2001) (9)
Phase 1 / 2 study to assess the safety , efficacy , and pharmacokinetics of barasertib ( AZD 1152 ) in patients with advanced acute myeloid leukemia (2011) (9)
The prognostic significance of chromosomal findings in patients with acute myeloid leukemia in a study comparing the efficacy of autologous and allogeneic bone marrow transplantation. (1991) (9)
Enhancement of erythropoietin-stimulated cell proliferation by Anandamide correlates with increased activation of the mitogen-activated protein kinases ERK1 and ERK2. (2000) (9)
Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia (2020) (9)
Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia (2020) (9)
Heterogeneity of proliferative responses of human B cell precursor acute lymphoblastic leukemia (BCP-ALL) cells to interleukin 7 (IL-7): no correlation with immunoglobulin gene status and expression of IL-7 receptor or IL-2/IL-4/IL-7 receptor common gamma chain genes. (1995) (9)
GM-CSF receptor targeted treatment of primary AML in SCID mice using Diphtheria toxin fused to huGM-CSF (1998) (9)
High-dose methotrexate with leucovorin rescue: effectiveness in relapsed hairy cell leukemia. (1985) (9)
The role of bone marrow transplantation in adult acute lymphocytic leukemia. (1993) (9)
The impact of medical education and networking on the outcome of leukemia treatment in developing countries. The experience of International Consortium on Acute Promyelocytic Leukemia (IC-APL) (2012) (9)
An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens (2018) (8)
ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia (2012) (8)
Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML (2017) (8)
A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC (2013) (8)
Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia (2022) (8)
Acute promyelocytic leukemia with a PLZF-RARalpha fusion protein. (2001) (8)
A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group. (1990) (8)
Comparative analysis of IL-1 regulated and spontaneous growth of acute myeloid leukemia in vitro. (1990) (8)
High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study (2006) (8)
Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (>= 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15) (2017) (8)
Phase II study of lomustine, cytarabine, mitoxantrone, and prednisone (CAMP) combination chemotherapy for doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphoma. (1990) (7)
Molecular remission of Philadelphia/bcr‐abl‐positive acute myeloid leukaemia after treatment with anti‐CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA‐676) (2000) (7)
Treatment of acute myelogenous leukaemia (1997) (7)
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. (2020) (7)
Retroviral transfer of the multidrug resistance‐1 gene into lineage‐committed and primitive hemopoietic cells (1995) (7)
Cytokines and Growth Factors in Blood Transfusion (1997) (7)
CD20 and CD40 mediated mitogenic responses in B‐lineage acute lymphoblastic leukaemia (1996) (7)
The impact of CD4+Foxp3+ Treg on immunity to murine cytomegalovirus after bone marrow transplantation depends on the peripheral or thymic source of T cell regeneration. (2010) (7)
[Allogenic bone marrow transplantation in men]. (1975) (7)
Keratinocyte Growth Factor Improves Allogeneic Bone Marrow Engraftment through a CD4+Foxp3+ Regulatory T Cell-Dependent Mechanism1 (2009) (7)
FETAL LIVER CELL TRANSPLANTATION (1975) (7)
Practical aspects and diagnostic significance of in vitro manipulation of progenitors in human acute myeloid and lymphoid leukaemia. (1991) (6)
Hematopoietic growth factors and progenitor cells in human acute leukemia. (1990) (6)
The Common Viral Insertion Site Evi12 Is Located in the 5′-Noncoding Region of Gnn, a Novel Gene with Enhanced Expression in Two Subclasses of Human Acute Myeloid Leukemia (2005) (6)
Fetal liver cell transplantation : role and nature of the fetal haemopoietic stem cell (1975) (6)
Lead-in Dose Optimization to Mitigate Cytokine Release Syndrome in AML and MDS Patients Treated with Flotetuzumab, a CD123 x CD3 Dart® Molecule for T-Cell Redirected Therapy (2017) (6)
Haemopoietic growth factors in acute myeloblastic and lymphoblastic leukaemia. (1992) (6)
MicroRNA-155 induces AML in combination with the loss of C/EBPA in mice (2016) (6)
a study of 319 de novo AML patients High EVI1 expression predicts poor survival in acute myeloid leukemia (2013) (6)
Involvement of tumor necrosis factor (TNF) receptors p55 and p75 in TNF responses of acute myeloid leukemia blasts in vitro (1992) (6)
Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials (2020) (6)
The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood (2014) (6)
Analysis of the TNF receptors on human leukaemia cells by affinity cross‐linking (1992) (6)
[A patient with acute leukemia and meningitis caused by Staphylococcus epidermidis treated with fosfomycin]. (1995) (6)
Germline loss of MBD4 predisposes to leukaemia due to a mutagenic cascade driven by 5mC (2017) (5)
A Multicentre Phase II Study of the Aminopeptidase Inhibitor, CHR- 2797, in the Treatment of Elderly and/or Previously Treated patients with Acute Myeloid Leukemia. (2008) (5)
Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab (2020) (5)
Cell to cell contact enhances the proliferation of acute myeloid leukemia (AML) cells in vitro without an apparent role of adhesion glycoproteins LFA1, MAC1 and P150-95. (1989) (5)
Clinical use of hematopoietic growth factors. (1994) (5)
Introduction to the review series on leukemic stem cells. (2017) (5)
Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis (2021) (5)
Somatostatin receptor scintigraphy in cutaneous malignant lymphomas. (1996) (5)
Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia. (1987) (5)
BONE MARROW TRANSPLANTATION STRATEGIES IN ACUTE LEUKAEMIA (1984) (5)
Autologous bone marrow transplantation in acute myeloid leukemia in first remission: first Dutch prospective study. (1990) (5)
MESNUM AND CYCLOPHOSPHAMIDE CYSTITIS (1980) (5)
Introduction of the human interleukin-6 (IL-6) receptor in murine IL-3- dependent hematopoietic cells restores responsiveness to IL-6 (1992) (5)
Lymphocyte recovery following allogeneic stem cell transplantation: New possibilities for improvement (2002) (5)
Maturation hierarchy of leukemic stem cells (1998) (5)
[Treatment results and the prognosis in patients with localization of non-Hodgkins-lymphoma in the central nervous system]. (1998) (5)
Peripheral blood progenitor cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia (1997) (5)
DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia (2021) (4)
Therapy of Acute Myeloid Leukemia in Adults (2003) (4)
Detection of mutant NPM1 mRNA in acute myeloid leukemia using custom gene expression arrays. (2013) (4)
Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center (2013) (4)
Role of interleukin-7 in the growth of acute lymphoblastic leukemia. (1990) (4)
Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols (2019) (4)
Leukemic karyotype in CFU-C of a patient with acute myelomonocytic leukemia. (1983) (4)
recommendations from an international expert panel, on behalf of the Diagnosis and management of acute myeloid leukemia in adults: (2010) (4)
Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON leukemia group trials (2013) (4)
Introduction to a review series on myelodysplastic syndromes. (2019) (4)
Hematopoietic growth factors and human acute leukemia. (1988) (4)
A Phase I Study of CHR-2797, an Orally Active Aminopeptidase Inhibitor in Elderly and/or Treatment Refractory Patients with Acute Myeloid Leukemia or Multiple Myeloma. (2007) (4)
Transplantation of fetal liver cells in the treatment of severe combined immunodeficiency disease (1977) (4)
Another look at imatinib mesylate. (2007) (4)
TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia (2020) (4)
Treatment Costs and Quality of Life with Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Antineoplastic Therapy—Related Febrile Neutropenia (1997) (4)
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS (2021) (4)
Final analysis of a randomized study on the value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML (2002) (4)
LEUKEMIC STEM CELL FREQUENCY COMBINED WITH MRD IS AN IMPORTANT BIOMARKER TO PREDICT RELAPSE IN ACUTE MYELOID LEUKEMIA. RESULTS FROM A PROSPECTIVE H102 STUDY (2017) (4)
The Growth Factor Independence 1 variant form GFI136N Predisposes to Acute Myeloid Leukemia by Inducing Epigenetic Changes in Oncogenes Such As Hoxa9 (2011) (4)
Reply to ‘Response to proposal for a novel cancer drug pricing model’ (2018) (3)
Hematopietic Cell Transplantation after a Low-Dose, Total-Body Irradiation Based Regimen in Elderly Patients with AML: A Multicenter, Multinational, Prospective HOVON/SAKK/OSHO Study. (2006) (3)
Mutant Wilms’ Tumor 1 (WT1) mRNA with Premature Termination Codons Is Sensitive to Nonsense-Mediated RNA Decay in Acute Myeloid Leukemia (AML) (2008) (3)
Granulocyte-macrophage colony stimulating factor (GM-CSF) in the treatment of hematological malignancies (1993) (3)
[The role of cost analysis in the evaluation of the development of medical technology. The case of allogenic stem-cell transplantation]. (2004) (3)
Quantitative evaluation of intracellular uptake of daunorubicin in acute myeloid leukemia: A method analysis (2004) (3)
High rates of molecular response and low incidence of mutations in patients treated with newly diagnosed chronic myeloid leukemia (CML) treated with a dose-escalated combination of imatinib and cytarabin. (2004) (3)
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome (vol 93, pg 1894, 2008) (2007) (3)
Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort (2021) (3)
[Management in paraproteinemia]. (1992) (3)
The Regulation of mRNA Translation Controls the Balance between Expansion and Differentiation of Erythroid Progenitors. (2004) (3)
Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias (2011) (3)
Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia (2015) (3)
P-gp and mrp activities in relation to treatment outcome in acute myeloid leukemia. (1999) (3)
Sex disparity in acute myeloid leukemia - evidence from a study of FLT3-ITD mutated patients (2020) (3)
Autologous Bone Marrow Transplantation in Patients with AML without Tumor Cell Purging and Post Transplant Chemotherapy (1984) (3)
8 Acute myeloid leukemia (2010) (3)
High Prognostic Impact of Flowcytometric Minimal Residual Disease Detection In Acute Myeloid Leukemia: Prospective Data From the HOVON/SAKK 42a Study (2010) (3)
[The diagnosis of acute myeloid leukaemia enhanced by using DNA microarrays]. (2005) (3)
Double, but Not Single, CEBPA mutations Define a Subgroup of Acute Myeloid Leukemia with Favorable Outcome and a Distinct Gene Expression Profile (2008) (3)
Introduction of the human interleukin-6 (IL-6) receptor in murine IL-3-dependent hematopoietic cells restores responsiveness to IL-6. (1992) (3)
Hematopoietic growth factors and in vitro growth of human acute myeloblastic leukemia. (1990) (3)
PCN1 COST ANALYSIS OF HLA-IDENTICAL SIBLING AND VOLUNTARY UNRELATED ALLOGENEIC BONE MARROW AND PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN ADULTS WITH ACUTE MYELOCYTIC LEUKAEMIA OR ACUTE LYMPHOBLASTIC LEUKAEMIA (2002) (3)
PF255 INCIDENCE AND RISK FACTORS FOR EARLY DEATH AMONG 2421 APL PATIENTS: THE PETHEMA REGISTRY EXPERIENCE (2019) (3)
Dirk Willem van Bekkum: a pioneer in haematology, transplantation and radiobiology (1925–2015) (2015) (3)
Two Different EVI1 Expressing Poor-Risk AML Subgroups with Distinct Epigenetic Signatures Uncovered by Genome Wide DNA Methylation Profiling (2008) (3)
Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (2019) (3)
Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy (2019) (3)
Criteria for complete remission in acute myeloid leukemia revisited. (2003) (2)
Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS ≥ 1.5) (2008) (2)
Improved peripheral blood stem cell collection by GM-CSF stimulation in patients with multiple myeloma (1990) (2)
Epigenetic Signatures Identify New Clinically Relevant Subtypes and Define Gene Regulatory Patterns in Patients with Acute Myeloid Leukemia (AML) (2008) (2)
Acute lymphoblastic leukaemia in adults: Immunological subtypes and clinical features at presentation (1993) (2)
Publisher Correction: miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia (2018) (2)
A Novel Subgroup of Poor Prognostic AML with Low CEBPA Expression, CEBPA Promoter Hypermethylation and DNMT3b Overexpression. (2004) (2)
Post-Remission Treatment with Allogeneic Stem Cell Transplantation Improves Outcome in Patients Aged 60 Years and Older with Acute Myeloid Leukemia in First Remission (2014) (2)
Patterns of Bone Marrow Micro Vessel Morphology in AML and High Risk MDS Predict Treatment Outcome Following Intensive Chemotherapy and Bevacizumab (2011) (2)
AML beyond the boundaries of daunomycin and cytarabine (2003) (2)
Quantitative studies on the take of fetal liver hemopoietic trans- plants. (1975) (2)
IL-7-mediated protection against minor-antigen-mismatched allograft rejection is associated with enhanced recovery of regulatory T cells. (2007) (2)
AML Cell Heterogeneity. Implications for Leukemia Cell Separation from Autologous Bone Marrow Grafts (1984) (2)
A randomized study on the value of Fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. A report from the Dutch-Belgian hemato-oncology cooperative group (HOVON) (2001) (2)
Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia (2021) (2)
Changing of the guard. (2013) (2)
In vitro chemotherapy with ASTA-Z-7557: studies in rat and human acute myeloid leukemia (1984) (2)
Daunorubicin and Cytarabine Compared with Daunorubicin, Cytarabine and the MDR1 Reversal Agent PSC-833 in Elderly Patients with Acute Myelogenous Leukemia. (2004) (2)
Analysis of the breakpoints in translocation (15;17) Observed in 4 patients with acute promyelocytic leukemia (1982) (2)
Treatment of patients with acute myeloid leukemia in first remission with marrow ablative therapy and autologous bone marrow transplantation. (1987) (2)
995OInterim results from a phase 1 first-in-human study of flotetuzumab, a CD123 x CD3 bispecific DART molecule, in AML/MDS (2017) (2)
Blood's 70th anniversary: a rich history. (2015) (1)
How I Treat How I treat the older patient with acute myeloid leukemia (2015) (1)
Allogeneic T-cell depleted blood stem cell transplantation versus T-cell depleted bone marrow transplantation: a prospective randomized multicenter study (2003) (1)
Retinoic acid-dependent gene transactivation by PML-RAR without direct DNA-binding. (2005) (1)
Activated RAS Oncogenes in Acute Leukemia (1986) (1)
Response: Allogeneic hematopoetic stem-cell transplantation in acute myeloid leukemia (2007) (1)
No detection of macrophage erythropoietin production in bone marrow from rheumatoid arthritis patients with and without anaemia and controls (1991) (1)
Hyperoxia Induces Defective Epo-Induced Signal Transduction and Loss of Expansion Capacity in Fanca- and Fancg-Deficient Erythroid Progenitors. (2004) (1)
signature TRIADs : a new class of proteins with a novel cysteine-rich (1999) (1)
Prognostic and Functional Relevance of Aberrant Microrna-9/9* Expression in Acute Myeloid Leukemia. (2012) (1)
prognostic significance association with other gene abnormalities and previously established gene Mutations in nucleophosmin NPM 1 in acute myeloid leukemia ( AML ) : (2005) (1)
PU.1 Is Essential For MLL Leukemia Via Activation Of The Meis/HOX Pathway and A Monocytic Cytokine Mediated Anti-Apoptotic Inflammatory Program (2013) (1)
The long road: improving outcome in elderly "unfit" AML? (2020) (1)
Hematology in 2000 and beyond: a weather forecast. (1999) (1)
Working Group (IWG) response criteria in myelodysplasia Clinical application and proposal for modification of the International (2009) (1)
Infrequent Phenotypes of Clonogenic Cells in AML: Evidence for Abnormal Differentiation and Possibilities for Detecting Minimal Disease? (1987) (1)
OC-10 - Disseminated intravascular coagulation at diagnosis strongly predicts both arterial and venous thrombosis in acute myeloid leukemia patients. (2016) (1)
SP1 and NF-Y-Dependent Gene Transactivation Defines a Gain-of-Function for the PML-RARα Oncoprotein. (2005) (1)
Is the Basis of Cleaning Autologous Bone Marrow Transplants in Leukemia Strong Enough (1984) (1)
Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT (2016) (1)
Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia (2020) (1)
Clinical Cancer Research Collaborative Group (SAKK) and for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), and Swiss Group for (2011) (1)
[New dimensions in the treatment of cancer?]. (1980) (1)
Introduction to a review series on hematologic disease at older age. (2018) (1)
Clinical Useful Prognostic Index for Adult Patients with Acute Myeloid Leukemia in First Relapse. (2004) (1)
Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation (2021) (1)
Unique Gene Expression Profiles of AML Patients with CEBPA Mutations. (2005) (1)
[Diagnosis and treatment of non-Hodgkin lymphoma in Netherlands: variation in guidelines and in practice]. (2000) (1)
Abstract CT035:TP53abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia (2020) (1)
Randomized placebo controlled trial of GM-CSF in patients with chemotherapy related febrile neutropenia (1995) (1)
Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study (2022) (1)
Extensive Molecular Analysis Strongly Improves the Distinction Between AML and ALL in Adult Acute Leukemias of Ambiguous Lineage (2014) (1)
TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia (2020) (1)
analysis benefits for whom? results of a HOVON/SAKK donor versus no donor remission acute myeloid leukemia in young and middle aged adults: Myeloablative HLA-identical sibling stem cell transplantation in first (2013) (1)
PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse (2021) (1)
Patterns of Primary Treatment, Trial Participation and Survival in Adult Acute Myeloid Leukemia: A Nationwide Population-Based Study Among Patients Diagnosed in the Netherlands from 1989 to 2012 (2014) (1)
Allogeneic Hematopoietic-Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40-60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning (2011) (1)
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome (2022) (1)
Risk-adapted treatment of acute promyeliacytic leukemia : Updated results of the Spanish PETHEMA LPA99 trial using ATRA and anthracycline monochemotherapy (2007) (1)
Rotterdam experience with autologous bone marrow transplantation in patients with acute myeloid leukemia in first remission (1984) (1)
Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial. (2022) (1)
EORTC Leukemia Group trials on acute myeloid leukemias: an overview. (1990) (1)
The Use of Gradient Separated Stem Cell Grafts in HLA Matched Donor-Recipient Bone Marrow Transplantation (1985) (1)
The gene NM23-M2 Is frequently mutated in leukemia (2000) (1)
Genetic vs. Epigenetic Disruption of the CEBPA Locus Yields Epigenomically and Biologically Distinct Leukemia Phenotypes. (2007) (1)
[Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in patients with leukemia]. (1986) (1)
[STI571: a new dimension in the treatment of chronic myeloid leukemia]. (2002) (1)
GRAFT VERSUS LEUKEMIA EFFECT OF ALLOGENEIC STEM CELL TRANSPLANTATION AND MINIMAL RESIDUAL DISEASE IN PATIENTS WITH AML IN FIRST COMPLETE REMISSION (2017) (1)
MicroRNAs in Normal Human Terminal Granulocytic Differentiation. (2009) (1)
CHR-2845, a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor In a First In Man Clinical Trial In Subjects with Advanced Haematological Malignancies (2010) (1)
Long Term Outcome After Low Dose TBI Based Conditioning Hematopoietic Stem Cell Transplantation (HSCT) From Related and Unrelated Donors for Older Patients with AML (2011) (1)
Acceleration and Enhancement of T-Cell Recovery and Immune Competence by Flt3-Ligand (Flt3L) Following BMT with Low Numbers of Progenitor Cells in Immune Deficient Mice. (2004) (1)
In vitro colony growth of acute myelogenous leukemia. (1976) (1)
Randomized P lacebo-Controll ed T rial o f G r anulocyte- M a crophage C olony-Stimulati ng F actor i n P atients W ith Chemotherapy-Rel ated F ebrile N e utropenia (1996) (0)
route for G- CSF-mediated activation of signaling complexes of the p21ras required (G-CSF) receptor, implicated in the activation of JAK2, is also Tryptophan 650 of human granulocyte colony-stimulating factor (2011) (0)
Gfi1 As a Novel Prognostic Marker and Tumor Suppressor In Acute Myeloid Leukemia (2013) (0)
disease following T-cell-depleted SCT cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem (2010) (0)
gene expression signatures and their favorable prognostic significance association with other gene abnormalities and previously established in acute myeloid leukemia ( AML ) : ( NPM 1 ) Mutations in nucleophosmin (2005) (0)
EBV reactivation and lymphoproliferative disease transplantation may identify patients at very high risk for progressive lymphocytes after partially T-depleted allogeneic stem cell specific CD8+ T -- Impaired recovery of Epstein-Barr virus (EBV) (2013) (0)
older age : a randomized phase 2 trial of the Dutch-Belgian Cooperative Addition of bevacizumab to chemotherapy in acute myeloid leukemia (2012) (0)
in CD34+ acute myeloid leukemia cells Predominance of functional multidrug resistance (MDR-1) phenotype (2011) (0)
Leukemia Identification of Disease Genes in Human Acute Myeloid Significance of Murine Retroviral Mutagenesis for Updated (2006) (0)
AML-234 Prognostic Value of FLT3-ITD Residual Disease in Acute Myeloid Leukemia. (2022) (0)
locus and accelerates K-RAS driven myeloproliferative disorder in mice Hoxa9 The human GFI136N variant induces epigenetic changes at the (2013) (0)
Correction (2004) (0)
The Peripheral Cannabinoid Receptor CB2 and CD40 Are Novel Biological Markers That Predict Outcome in Diffuse Large B-Cell Lymphoma of Elderly Patients. (2004) (0)
acute myeloid leukemia MicroRNA expression profiling in relation to the genetic heterogeneity of (2013) (0)
The added value of multi‐state modelling in a randomized controlled trial: The HOVON 102 study re‐analyzed (2021) (0)
Association between Nuclear SET Domain (NSD) Protein Lysine Methyltransferases (KMT) Expression and Poor Prognosis in Acute Promyelocytic Leukemia (APL) Patients Treated with ATRA and Anthracycline Protocol (2017) (0)
Prognostic Impact Of MLL5 transcript Levels On Outcome Of Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study (2013) (0)
DNMT3A Mutations Enhance CpG Mutagenesis through Deregulation of the Active DNA Demethylation Pathway (2016) (0)
Concise summary of the cytokines involved in human hematopoiesis (2004) (0)
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival. (2023) (0)
Keratinocyte Growth Factor Increases the CD4 + Foxp3 + Regulatory T Cell-Pool by an Early Thymus-Independent and a Late Thymus-Dependent Mechanism. (2006) (0)
Acute myeloid leukemia with CEBPA aberrations: alpha-Catenin and other putative CEBPA targets in leukemic transformation (2006) (0)
BAALC and EVI1 Prognostic Gene Expression in Adult Acute Myeloid Leukemia Using the Amlprofiler Custom Microarray (2012) (0)
Functionele consequenties van mutaties in de receptor tyrosine kinase c-KIT bij acute myeloïde leukemie (AML) met inv(16) (2005) (0)
Book Review Acute Myelogenous Leukemia (Contemporary Hematology.) Edited by Judith E. Karp. 426 pp., illustrated. Totowa, NJ, Humana Press, 2007. $149. 978-1-58829-621-4. (2007) (0)
Forkhead transcription factor Foxo-3a induces terminal differentiation of erythroid precursors by induction of BTG1, a co-activator of protein arginine methyl transferase 1. (2002) (0)
Gfi1 as a new target and predictive marker in AML (2014) (0)
Cost-effectiveness of autologous bone marrow transplantation in comparison to conventional chemotherapy in patients with non-Hodgkin's lymphoma (1994) (0)
2 receptors, and interleukin 2 stimulates in vitro colony formation Common and pre-B acute lymphoblastic leukemia cells express interleukin (2011) (0)
In vitro detection of clonogenic lymphoid leukemia/lymphoma cells (1986) (0)
Leukemic hematopoiesis in vitro: acute myeloid leukemia. (1989) (0)
Somatostatin receptor scintigraphy for the initial staging of Hodgkin's disease (1997) (0)
Distinct Gene Expression Profiling in AML in Elderly Versus Younger Patients. (2008) (0)
High Prognostic Impact of Mixed Chimerism of Blood and Marrow In the First Year After Allogeneic Hematopoietic Stem Cell Transplantation: The Need to Rapidly Establish Complete Donor Chimerism. (2010) (0)
The treatment of acute leukaemia in adults: a perspective. (1987) (0)
Mutant NPM1 MRD and FLT3-ITD Status are Independent Prognostic Factors for the Risk of Relapse in AML Patients (2016) (0)
P-glycoprotein and CD34 double expression and altered Ara-C metabolism are associated with autonomous proliferation in adult acute myeloid leukemia: 111 (1994) (0)
[Current therapy of acute promyelocytic leukemia using vitamin A derivatives]. (1993) (0)
A Single Microarray Assay for Simultaneous Diagnosis of t(15;17), t(8;21), Inv(16)/t(16;16), NPM1 Type A/B/D Mutation, CEBPA Double Mutation, and Aberrant Expression of BAALC or EVI1 in AML/APL Patients (2011) (0)
RAS mutations are frequent events in AML, with their report- ed frequency being up to 30%. (2004) (0)
[AML-6 and AML-7 studies on the treatment of acute myelocytic leukemia. Cyclic alternating chemotherapy during remission, and induction of remission and survival of elderly patients]. (1985) (0)
Platelet transfusion and alloimmunization. (1982) (0)
The EORTC-HOVON Approach to the Older Patient with AML: The Use of GM CSF (2001) (0)
prospective sibling donor versus no-donor comparison adult patients with acute lymphoblastic leukemia in first remission: a Myeloablative allogeneic versus autologous stem cell transplantation in (2013) (0)
The Gene Encoding Nuclear Erythroid Factor 2 (NFE2) Is Recurrently Mutated in Acute Myeloid Leukemia (2012) (0)
[Transplantation of autologous bone marrow in 3 patients with acute myeloid leukemia in first remission; initial experiences with a new treatment]. (1983) (0)
prognosis of adult acute myeloid leukemia Relation between CXCR-4 expression, Flt3 mutations and unfavourable (2013) (0)
Textbook of Malignant Haematology, Second Edition (2004) (0)
[Non-ketoacedotic, hyperglycemic, hyperosmolar diabetic coma in children]. (1986) (0)
[On the road to cure of multiple myeloma?]. (1992) (0)
Translation of IGBP1 mRNA Contributes to the Regulation of Expansion and Differentiation of Erythroid Progenitors. (2005) (0)
The Tyrosine Kinase Receptor RON Is Phosphorylated upon Epo-Receptor Activation, Mediates Expansion and Inhibits Differentiation of Erythroid Progenitors (2002) (0)
Identification of the Evi12 proto-oncogene and its role in leukemogenesis (2000) (0)
Autologous bone marrow transplantation in first remission AML--its relative value. (1990) (0)
with acute myeloid leukemia ) is associated GFI1 ( Growth Factor Independence 1 A variant allele of (2010) (0)
marrow precursors: importance of accessory cells Stimulating spectrum of human recombinant multi-CSF (IL-3) on human (2011) (0)
The Comparative Value of Hematopoietic Stem Cell Transplantation and Chemotherapy in Cytogenetically Normal AML Subclassified By NPM1 Mutation Status and FLT3-ITD Allelic Ratio (2014) (0)
Randomized induction and post induction therapy in adult patients (≤ 60 yrs of age) with acute myelocytic leukemia (AML) or refractory anemia with excess of blasts (RAEB, RAEB-t) with IPSS score ≥ 1.5 (2005) (0)
Blood Spotlight Sense and nonsense of high-dose cytarabine for acute myeloid leukemia (2012) (0)
Abstract 1366:MBD4guards against DNA damage from methylcytosine deamination (2018) (0)
colony-forming cells retain growth factor (interleukin 2) dependence Acute lymphoblastic leukemia and non-Hodgkin's lymphoma of T lineage: (2011) (0)
Professor Anton Hagenbeek 1948–2021: Father of MRD and lymphoma expert (2021) (0)
Identification of signal transduction pathways and target genes of the stem cell factor receptor c-KIT (2000) (0)
Salvage Therapy with Chemotherapy- or Arsenic Trioxide-Based Regimens for Acute Promyelocytic Leukemia in First Relapse. (2009) (0)
[Hematopoietic growth factors in the limelight. New actors on the pharmacotherapeutic stage]. (1991) (0)
[Views on the financing of biomedical scientific research; the report 'Erop of eronder' (Sink or swim) from the KNAW (Royal Netherlands Academy of Arts and Sciences)]. (2006) (0)
In Vivo Pharmacokinetics of Daunorubicin in Bone Marrow in Adult Acute Nonlymphocytic Leukaemia (1984) (0)
[Bone marrow culture, a new method of study in hematology]. (1978) (0)
Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia (2019) (0)
inhibitor tipifarnib in acute myeloid leukemia A 2-gene classifier for predicting response to the farnesyltransferase (2007) (0)
Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of “Acute Myeloid Leukemia, Not Otherwise Specified” in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center (2012) (0)
Autologous Bone Marrow Transplantation in Acute Myeloblastic Leukemia (AML): In Vitro Studies to Detect Minimal Disease in Remission Marrow (1987) (0)
Defective internalization of granulocyte colony-stimulating factor (G-CSF) receptor mutants in patients with severe congenital neutropenia / acute myeloid leukemia (2001) (0)
Attempts at detection of clonogenic cells in residual leukemia (1986) (0)
with silenced CEBPA and mutations in NOTCH1 Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia (2013) (0)
Linking the Glycolytic Enzyme HK3 to Neutrophil Differentiation of APL Cells Via PU.1 (2011) (0)
Various Other 3 q Abnormalities in Acute Myeloid Leukemia (2010) (0)
P406: ENHANCED SIGNIFICANCE OF FLT3-ITD RESIDUAL DISEASE DETECTION ON TREATMENT OUTCOME IN ACUTE MYELOID LEUKEMIA (2022) (0)
OP38 Reduced intensity conditioning hematopoietic cell transplants in elderly patients with AML (2007) (0)
[Malignant disorders of the lymphatic system]. (1986) (0)
[Myelodysplastic syndromes: a group of preleukemic disorders]. (1987) (0)
Abstract 2199: Death Associated Protein Kinase 2 (DAPK2) is a novel transcriptional target of PML-RARA and PU.1 (SPI1) during neutrophil differentiation of acute promyelocytic leukemia (APL) cells (2012) (0)
[Is aplastic anemia an autoimmune disease?]. (1980) (0)
[Chronic benign neutropenia possibly caused by a plasma factor]. (1986) (0)
abnormal migration properties in a ligand-dependent manner blasts, either induces a neutrophilic differentiation block or confers The peripheral cannabinoid receptor Cb2, frequently expressed on AML (2011) (0)
AML-279 Molecularly-Defined De Novo and Secondary Acute Myeloid Leukemia Are Biologically and Clinically Different Entities. (2022) (0)
VEGFC Predicts Poor Outcome in Pediatric as Well as Adult Acute Myeloid Leukemia (2009) (0)
Autologous Blood Stem Cell Transplantation Results In Better Relapse-Free Survival Than Consolidation Chemotherapy : Results of a HOVON/SAKK Phase III Trial In 519 AML Patients In First Complete Remission (2010) (0)
Identification of a Subgroup of Biphenotypic Myeloid/T-Cell Acute Leukemias with a CEBPA-Mutant Gene Expression Profile, Frequent CEBPA Promoter Hypermethylation and NOTCH1 Mutations. (2006) (0)
ALLOGENEIC BONE MARROW TRANSPLANTATION FOR PRIMARY MYELOFIBROSIS (1992) (0)
Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia (2011) (0)
Analysis of antigenic determinants on human hematopoietic progenitor cells with respect to future purging studies (1986) (0)
Allogeneic Bone Marrow Engraftment Keratinocyte Growth Factor Improves (2009) (0)
Role of arsenic trioxide in front-line therapy (2006) (0)
Clinical trials have a home in Blood. (2014) (0)
and survival of APL cells PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation (2013) (0)
DNA Methylation Profiling Predicts Clinical Outcomes and Reveals Unique Insights Into the Molecular Complexity of Acute Myeloid Leukemia. (2009) (0)
Malignant transformation of hematopoietic stem cells: pathophysiology and development of therapy (1988) (0)
The Impact of Novel Molecular Markers on Risk Stratification in Acute Myeloid Leukemia (2012) (0)
ΔNp73/TAp73 Expression Ratio Is Associated with Poor Outcome in Acute Promyelocytic Leukemia, (2011) (0)
leukemia cells and monocytes colony-stimulating factor and interleukin-3 on human acute myeloid Common binding structure for granulocyte macrophage (2011) (0)
Reply to ‘Economic comments on proposal for a novel cancer drug pricing model’ (2018) (0)
[AML-7 study of the value of intensive remission induction in aged patients with acute myelocytic leukemia]. (1985) (0)
Running head: TIPIFARNIB IN REFRACTORY OR RELAPSED AML (2007) (0)
Differentiation Blockade : The Role of Transcription Factors in AML (2005) (0)
Gene transactivation without direct DNA binding deﬁnes a novel gain-of-function for PML-RAR (cid:1) (2008) (0)
Concluding remarks session VII—Experimental treatment (1977) (0)
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis (2022) (0)
Abstract LB-073: Epigenome evolution in relapsed acute myeloid leukemia (2016) (0)
Mitoxantrone and VP-16,213 (MVP16) in AML Patients Refractory to Cytosine Arabinoside with Daunorubicin and High-Dose Cytosine Arabinoside with Amsidine: Preliminary Results (1992) (0)
bone marrow cultures No stimulative effect of adipocytes on hematopoiesis in long-term human (2011) (0)
leukemia Granulocyte colony-stimulating factor receptors in human acute myelocytic (2011) (0)
Severe Chronic Neutropenia Granulocyte Colony-Stimulating Factor Receptor Gene Associated With Perturbed Granulopoiesis in Mice With a Targeted Mutation in the (1998) (0)
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (2020) (0)
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (2020) (0)
Prof. Anton Hagenbeek 1948–2021: Father of MRD and Lymphoma Expert (2021) (0)
Reconstitution of CMV-specific CD8+ T-cells following allogeneic stem cell transplantation (SCT): Evaluation of tetramers for prediction of recurrent CMV reactivation (2004) (0)
[Bacteriologic management of patients with decreased resistance]. (1984) (0)
University of Groningen Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia Weinhäuser, (2020) (0)
Leukemia and myelodysplasia. (1993) (0)
Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements (2022) (0)
Papers to be published in forthcoming issues (2005) (0)
One-Mutation Model Can Explain Age Incidence in AML Carrying Nucleophosmin (NPM1) Mutations. (2007) (0)
PSY4 CHALLENGES IN USING THE LITERATURE TO ESTIMATE THE OUTCOMES OF CURRENT RISK STRATIFICATION METHODS IN ADULT PATIENTS WITH PRIMARY ACUTE MYELOID LEUKEMIA (2009) (0)
status at diagnosis previously untreated acute myeloid leukemia (AML), in relation to MDR1 daunorubicin and cytarabine in the treatment of elderly patients with The value of the MDR1 reversal agent PSC-833 in addition to (2013) (0)
Future Potential of Cytokines and Growth Factors in Transfusion Medicine: What New Horizons are There to Come? (1997) (0)
Poor-Risk Acute Leukemia Patients with An EBMT Low-Risk Score and An 8/8 Matched Unrelated Donor Show Excellent Survival After Hematopoietic Stem Cell Transplantation. (2009) (0)
Bone-marrow purging with monoclonal antibodies and human complement in ALL and AML. (1987) (0)
Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial. (2023) (0)
[Successful bone marrow transplantation in a patient with non-Hodgkin lymphoma of high-grade malignancy with invasion of the central nervous system]. (1985) (0)
The comparison of somatostatin receptor and 67-gallium scintigraphy in the staging of malignant lymphomas (1997) (0)
[Myelodysplastic syndromes]. (1987) (0)
Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia (2019) (0)
AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial. (2022) (0)
Aberrant expression of the MLL5, BAALC, ID1, and WT1 genes is associated with higher induction mortality and poorer overall survival in acute promyelocytic leukemia patients treated with atra and anthracycline-based chemotherapy: an international consortium on acute promyelocytic leukemia study (2012) (0)
3. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic hematopoietic stem cell transplantation and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted stem cell transplantation. (2001) (0)
Gene Expression Profiles with Signatures of Tumor Biology and Chemotherapy Sensitivity May Provide a Novel Approach to Maximize Response to Induction Therapy in Patients with Acute Myeloid Leukemia. (2008) (0)
Concentrations of ciclosporin in allogeneic bone marrow recipients (1987) (0)
Stem Cells Initiate Leukemia in Immunodeficient Mice, But Spares Normal Hemopoietic Factor Eliminates Acute Myeloid Leukemia Cells With the Potential to Diphtheria Toxin Fused to Granulocyte-Macrophage Colony-Stimulating (2013) (0)
[Moerman therapy; evaluation of a 50-year effort]. (1992) (0)
The HOXA/PBX3 Pathway Is an Attractive Therapeutic Target in MLL-Rearranged Acute Leukemia (2012) (0)
PCN51 POTENTIAL ECONOMIC AND HEALTH IMPACT OF GENOMICS AND PROTEOMICSTECHNOLOGY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (2008) (0)
The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study (2017) (0)
[Bone marrow transplantation in development]. (1978) (0)
Nm23-M2 is a proto-oncogene involved in leukemia, and located in the novel common virus integration site Ev113 (1999) (0)
Somatostatin receptor scintigraphy for the initial staging of non-Hodgkin's lymphomas (1997) (0)
Functional consequences of mutations in the receptor tyrosine kinase c-KIT in AML with inv(16) (2005) (0)
1 BACKGROUND AND IMPLEMENTATION PLAN FOR THE EUROPEAN CANCER PATIENT’S BILL OF RIGHTS, 2016 (ARCHIVE) ECC Members (2017) (0)
UT1 The Calculation of Quality of Life Utilities for Acute Leukemia: A Comparison Between EQ5D-5L and QlQ-C30 (2012) (0)
Pathogenetic Significance of Retrovirus-Tagged Mouse Myeloid Leukemia Genes for Human AML. (2004) (0)
Depending on Receptor Activation Status Cannabinoid Receptor in Lymphoid Tissues Distinct Expression Profiles of the Peripheral (2004) (0)
In memoriam Mildred Scheel (1985) (0)
Autologous peripheral blood stem cell grafts are largely contaminated with malignant hematopoietic precursors despite repeated cycles of intensive chemotherapy. (1998) (0)
Defects in the RAS/RTK Signaling Pathways Predominate the Mutational Spectrum of EVI1/GATA2 Rearranged Myeloid Malignancies with Inv(3)/t(3;3) (2014) (0)
leukemic human megakaryoblasts Interleukin-6 (IL-6) is an intermediate in IL-1-induced proliferation of (2010) (0)
Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia (2018) (0)
OP06 Gene-expression micro-array in AML diagnostics (2007) (0)
Poster: AML-234 Prognostic Value of FLT3-ITD Residual Disease in Acute Myeloid Leukemia (2022) (0)
Interleukin-l a Also Induces Granulocyte-Macrophage Colony-Stimulating Factor in Immature Normal Bone Marrow Cells (2003) (0)
Blood (2020) (0)
Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching (2022) (0)
Presidential Symposium (2005) (0)
[Developments in the treatment of patients with chronic myeloid leukemia]. (1997) (0)
Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG (2014) (0)
Response to Yarranton (2005) (0)
vitro Interleukin 2 stimulates chronic lymphocytic leukemia colony formation in (2011) (0)
An Efficient Design for Cost-Effectiveness Studies of Personalized Medicine Strategies. (2014) (0)
Hematopoiesis: regulation of the proliferation and differentiation of hematopoietic progenitor cells (1988) (0)
receptors interleukin 2: functional characterization of the interleukin 2 membrane The proliferative response of B cell chronic lymphocytic leukemia to (2011) (0)
Metformintreatment Overcomes ATRA-Resistance in Acute Promyelocytic Leukemia and Increases FOXO3A Expression (2018) (0)
Selected lineage-associated antigens in hematopoietic cells (2004) (0)
MO3 THE DEVELOPMENT AND VALIDATION OF A DECISION MODEL REPRESENTING THE FULL DISEASE COURSE OF ACUTE MYELOID LEUKEMIA (2010) (0)
leukemia: flashback and prospects A decade of genome-wide gene expression profiling in acute myeloid (2010) (0)
Autologous BMT in acute myeloid leukaemia in first remission (Dutch prospective study). (1989) (0)
The Evolution of Evolutionary Thought (1959) (0)
NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia (2020) (0)
Immune Monitoring with iTAg™ MHC Tetramers*: Potential Clinical Utility in the Prediction of Recurrent CMV Reactivation in Allogeneic Stem Cell Transplant Recipients (2004) (0)
the proliferative response receptors on human acute myelocytic leukemia cells and relationship to Interleukin-3 and granulocyte-monocyte colony-stimulating factor (2011) (0)
Comparison Between RT-PCR and RQ-PCR for Minimal Residual Disease Detection in Acute Promyelocytic Leukemia: The International Consortium on Acute Promyelocytic Leukemia (IC-APL) Experience (2011) (0)
Nm23-M2 is frequently mutated in leukemia A novel mechanism of disregulated expression (2000) (0)
[Further developments in the treatment of acute myeloid leukemia with autologous bone marrow transplantation]. (1987) (0)
Allografting as Consolidative Immunotherapy for Older Patients with AML in Complete Remission Using Low Dose TBI, PBSC Infusion And Post- Transplant Immunosuppression With Cyclosporine And Mycophenolate (2002) (0)
Mechanism of protein kinase C mediated control of erythropoietin receptor signal transduction in normal and malignant erythropoiesis. (1999) (0)
Feasibility of HSCT vs consolidation therapy for AML patients aged 60-75 in CR1: A randomized phase III, multicentre EBMT study. (2018) (0)
Platelet transfusion and alloimmunization [letter] (1982) (0)
Age-specific differences in oncogenic pathway deregulation and chemosensitivity in patients with acute myeloid leukemia: Strategies to maximize response to induction chemotherapy. (2016) (0)
[Nobel Prize Medicine 1990 to transplantation researchers]. (1991) (0)
[Allogeneic bone marrow transplantation of unrelated donors; fewer complication, more donors]. (1997) (0)
Acute en chronische leukemie (2011) (0)
immature acute leukemia with myeloid/T-lymphoid features Genome-wide epigenetic analysis delineates a biologically distinct (2009) (0)
Genome-wide approaches to identify novel clinically relevant markers in acute myeloid leukemia with normal karyotypes (2007) (0)
Granulocyte-Macrophage Colony-stimulating Factor Receptors Alter Their Binding Characteristics during Myeloid Maturation through Up-regulation of the Affinity Converting , 8 Subunit ( KH 97 ) (2001) (0)
Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial (2022) (0)
Leukaemia and myeloma LEUKAEMIA AND MYELOMA | 424OI The efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients with acute myeloid leukemia in first relapse (2005) (0)
ADAMTS13: a new factor in the development of stroke? (2005) (0)
cells Fucose binding lectin for characterizing acute myeloid leukemia progenitor (2011) (0)

This paper list is powered by the following services:

Other Resources About Bob Löwenberg

en.wikipedia.org

What Schools Are Affiliated With Bob Löwenberg?

Bob Löwenberg is affiliated with the following schools:

Bob Löwenberg's Academic­Influence.com Rankings

Why Is Bob Löwenberg Influential?

Bob Löwenberg's Published Works

Published Works

Other Resources About Bob Löwenberg

What Schools Are Affiliated With Bob Löwenberg?

Bob Löwenberg's AcademicInfluence.com Rankings